Rachel received her Pharm.D. from the University of North Carolina’s Eshelman School of Pharmacy, during which she contributed to a number of oncology projects in a drug development and clinical pharmacology laboratory. She also held an internship position at IQVIA in Durham, North Carolina within the project leadership group. Before joining Nuventra, she completed the UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program, where her research focused on the safety and efficacy of direct oral anticoagulant (DOAC) medications, as well as chronic heart failure treatment disparities. Rachel has a particular interest in the development of individualized therapies.